Optimising first-line treatment for metastatic renal cell carcinoma
- 1 January 2020
- journal article
- letter
- Published by Elsevier BV in The Lancet
- Vol. 395 (10219), e8-E8
- https://doi.org/10.1016/s0140-6736(19)32594-2
Abstract
No abstract availableThis publication has 2 references indexed in Scilit:
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trialThe Lancet, 2019
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaThe New England Journal of Medicine, 2015